Clinical trial
Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine…
NCT00462215 · Alachua Government Services, Inc., Industry · Completed
Key facts
| NCT number | NCT00462215 |
|---|---|
| Title | Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) |
| Official title | An Open Label Phase III Study of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine to Assess the Immunogenicity and Safety and to Investigate the Need for and Timing of a Booster Vaccination |
| Lead sponsor | Alachua Government Services, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen |
| Enrollment | 550 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2007 |
| Completion | Feb 1, 2010 |
| First posted | Apr 18, 2007 |
| Last update posted | Oct 9, 2015 |
| Countries | Austria, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: